Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | CHIEF SCIENTIFIC OFFICER | February 05, 2024 | February 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date February 05, 2024 · Filed February 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,609 |
Ending reported balance
After 2024-02-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-02-05 · Exercise / conversion · Acquired 1,400 · Balance 3,009 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. Row 2 · 2024-02-05 · Exercise / conversion · Acquired 3,200 · Balance 6,209 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. Row 3 · 2024-02-05 · Sale · Disposed 4,600 · Balance 1,609 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.16 to $18.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 13,308 |
Reported balance
After 2024-02-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-05 · Exercise / conversion · Disposed 900 · Balance 13,308 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F3: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 9,088 |
Reported balance
After 2024-02-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-05 · Exercise / conversion · Disposed 500 · Balance 9,088 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F4: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01 | Direct | 10,894 |
Reported balance
After 2024-02-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-05 · Exercise / conversion · Disposed 500 · Balance 10,894 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F5: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01 | Direct | 34,908 |
Reported balance
After 2024-02-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-02-05 · Exercise / conversion · Disposed 1,200 · Balance 34,908 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F6: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01 | Direct | 41,732 |
Reported balance
After 2024-02-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-02-05 · Exercise / conversion · Disposed 1,500 · Balance 41,732 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023. F7: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.16 to $18.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F4: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F5: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.
F6: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
F7: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2023 Filed Jun 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 650 | $1.74 | $1,131.00 |
DisclosureSEC source: 0001415889-23-009390 · form4-06072023_060602.xml · nonDerivative · entry 1 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| May 05, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-007685 · form4-05092023_060501.xml · derivative · entry 9 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,232 Underlying: Common Stock · 750 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F8 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| May 05, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-007685 · form4-05092023_060501.xml · derivative · entry 8 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,408 Underlying: Common Stock · 650 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F7 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| May 05, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-007685 · form4-05092023_060501.xml · derivative · entry 7 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,294 Underlying: Common Stock · 200 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F6 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. Read SEC document |
| May 05, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-007685 · form4-05092023_060501.xml · derivative · entry 6 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,488 Underlying: Common Stock · 200 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F5 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 05, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-007685 · form4-05092023_060501.xml · derivative · entry 5 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,608 Underlying: Common Stock · 450 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F4 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 05, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 205 | $21.63 | $4,435.13 |
DisclosureSEC source: 0001415889-23-007685 · form4-05092023_060501.xml · nonDerivative · entry 4 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,609 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.225 to $21.805, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 05, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,045 | $20.79 | $42,521.69 |
DisclosureSEC source: 0001415889-23-007685 · form4-05092023_060501.xml · nonDerivative · entry 3 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,814 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.22 to $21.15, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 05, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,600 | $2.14 | $3,424.00 |
DisclosureSEC source: 0001415889-23-007685 · form4-05092023_060501.xml · nonDerivative · entry 2 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| May 05, 2023 Filed May 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 650 | $1.74 | $1,131.00 |
DisclosureSEC source: 0001415889-23-007685 · form4-05092023_060501.xml · nonDerivative · entry 1 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-006376 · form4-04072023_060401.xml · derivative · entry 9 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,982 Underlying: Common Stock · 750 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F8 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-006376 · form4-04072023_060401.xml · derivative · entry 8 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,058 Underlying: Common Stock · 650 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F7 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-006376 · form4-04072023_060401.xml · derivative · entry 7 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,494 Underlying: Common Stock · 200 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F6 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-006376 · form4-04072023_060401.xml · derivative · entry 6 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,688 Underlying: Common Stock · 200 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F5 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-006376 · form4-04072023_060401.xml · derivative · entry 5 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,058 Underlying: Common Stock · 450 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F4 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 535 | $19.11 | $10,221.50 |
DisclosureSEC source: 0001415889-23-006376 · form4-04072023_060401.xml · nonDerivative · entry 4 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,609 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.78 to $19.51, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,715 | $17.91 | $30,720.80 |
DisclosureSEC source: 0001415889-23-006376 · form4-04072023_060401.xml · nonDerivative · entry 3 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,144 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.63 to $18.45, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,600 | $2.14 | $3,424.00 |
DisclosureSEC source: 0001415889-23-006376 · form4-04072023_060401.xml · nonDerivative · entry 2 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 650 | $1.74 | $1,131.00 |
DisclosureSEC source: 0001415889-23-006376 · form4-04072023_060401.xml · nonDerivative · entry 1 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-004512 · form4-03082023_060305.xml · derivative · entry 9 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,732 Underlying: Common Stock · 750 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F8 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-004512 · form4-03082023_060305.xml · derivative · entry 8 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,708 Underlying: Common Stock · 650 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F7 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-004512 · form4-03082023_060305.xml · derivative · entry 7 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,694 Underlying: Common Stock · 200 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F6 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-004512 · form4-03082023_060305.xml · derivative · entry 6 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,888 Underlying: Common Stock · 200 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F5 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-004512 · form4-03082023_060305.xml · derivative · entry 5 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,508 Underlying: Common Stock · 450 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F4 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 45 | $24.92 | $1,121.58 |
DisclosureSEC source: 0001415889-23-004512 · form4-03082023_060305.xml · nonDerivative · entry 4 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.755 to $24.96, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,205 | $23.73 | $52,318.04 |
DisclosureSEC source: 0001415889-23-004512 · form4-03082023_060305.xml · nonDerivative · entry 3 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,654 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.445 to $24.38, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,600 | $2.14 | $3,424.00 |
DisclosureSEC source: 0001415889-23-004512 · form4-03082023_060305.xml · nonDerivative · entry 2 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 650 | $1.74 | $1,131.00 |
DisclosureSEC source: 0001415889-23-004512 · form4-03082023_060305.xml · nonDerivative · entry 1 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $25.57 | $0.00 |
DisclosureSEC source: 0001415889-23-002169 · form4-02082023_060201.xml · derivative · entry 9 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2033-02-06 F8 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on March 7, 2023. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-002169 · form4-02082023_060201.xml · derivative · entry 8 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,482 Underlying: Common Stock · 750 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F7 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-002169 · form4-02082023_060201.xml · derivative · entry 7 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,358 Underlying: Common Stock · 650 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F6 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-002169 · form4-02082023_060201.xml · derivative · entry 6 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,894 Underlying: Common Stock · 200 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F5 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-002169 · form4-02082023_060201.xml · derivative · entry 5 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,088 Underlying: Common Stock · 200 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F4 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-002169 · form4-02082023_060201.xml · derivative · entry 4 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,958 Underlying: Common Stock · 450 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F3 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,250 | $24.27 | $54,612.00 |
DisclosureSEC source: 0001415889-23-002169 · form4-02082023_060201.xml · nonDerivative · entry 3 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.84 to $24.74, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,600 | $2.14 | $3,424.00 |
DisclosureSEC source: 0001415889-23-002169 · form4-02082023_060201.xml · nonDerivative · entry 2 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 650 | $1.74 | $1,131.00 |
DisclosureSEC source: 0001415889-23-002169 · form4-02082023_060201.xml · nonDerivative · entry 1 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-000708 · form4-01092023_060101.xml · derivative · entry 8 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,232 Underlying: Common Stock · 750 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F7 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-000708 · form4-01092023_060101.xml · derivative · entry 7 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,008 Underlying: Common Stock · 650 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F6 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-000708 · form4-01092023_060101.xml · derivative · entry 6 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,094 Underlying: Common Stock · 200 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F5 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-000708 · form4-01092023_060101.xml · derivative · entry 5 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,288 Underlying: Common Stock · 200 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F4 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-000708 · form4-01092023_060101.xml · derivative · entry 4 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,408 Underlying: Common Stock · 450 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F3 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,250 | $26.40 | $59,404.50 |
DisclosureSEC source: 0001415889-23-000708 · form4-01092023_060101.xml · nonDerivative · entry 3 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.21 to $26.74, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,600 | $2.14 | $3,424.00 |
DisclosureSEC source: 0001415889-23-000708 · form4-01092023_060101.xml · nonDerivative · entry 2 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 650 | $1.74 | $1,131.00 |
DisclosureSEC source: 0001415889-23-000708 · form4-01092023_060101.xml · nonDerivative · entry 1 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012183 · form4-12072022_061201.xml · derivative · entry 8 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,982 Underlying: Common Stock · 750 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F7 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 650 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012183 · form4-12072022_061201.xml · derivative · entry 7 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,658 Underlying: Common Stock · 650 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F6 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-012183 · form4-12072022_061201.xml · derivative · entry 6 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,294 Underlying: Common Stock · 200 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F5 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-012183 · form4-12072022_061201.xml · derivative · entry 5 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,488 Underlying: Common Stock · 200 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F4 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 450 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-22-012183 · form4-12072022_061201.xml · derivative · entry 4 NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,858 Underlying: Common Stock · 450 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 6, 2022. F3 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.